drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00863 | DB06589 | 1,194 | 1,250 | [
"DDInter1568",
"DDInter1400"
] | Ranitidine | Pazopanib | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1194,
25,
1250
]
],
[
[
1194,
6,
7950
],
[
7950,
45,
1250
]
],
[
[
1194,
21,
28658
],
[
28658,
60,
1250
]
],
[
[
1194,
63,
479
],
[
47... | [
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopani... | Ranitidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound)
Ranitidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil... |
DB00281 | DB06273 | 608 | 980 | [
"DDInter1066",
"DDInter1824"
] | Lidocaine | Tocilizumab | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 J... | Moderate | 1 | [
[
[
608,
24,
980
]
],
[
[
608,
24,
143
],
[
143,
24,
980
]
],
[
[
608,
63,
494
],
[
494,
24,
980
]
],
[
[
608,
35,
1401
],
[
1401,
2... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mexiletine"
],
[
... | Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Mexiletine and Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disop... |
DB00789 | DB01203 | 1,431 | 699 | [
"DDInter796",
"DDInter1255"
] | Gadopentetic acid | Nadolol | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Moderate | 1 | [
[
[
1431,
24,
699
]
],
[
[
1431,
24,
729
],
[
729,
1,
699
]
],
[
[
1431,
21,
28882
],
[
28882,
60,
699
]
],
[
[
1431,
24,
278
],
[
278,
... | [
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
]
],
[
[
"Gadopentetic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
... | Gadopentetic acid may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol (Compound) resembles Nadolol (Compound)
Gadopentetic acid (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Nadolol (Compound)
Ga... |
DB00242 | DB09036 | 1,064 | 812 | [
"DDInter392",
"DDInter1668"
] | Cladribine | Siltuximab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
1064,
25,
812
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
812
]
],
[
[
1064,
25,
287
],
[
287,
63,
812
]
],
[
[
1064,
24,
496
],
[
496,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Cladribine may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarat... |
DB09046 | DB09083 | 1,094 | 880 | [
"DDInter1201",
"DDInter996"
] | Metreleptin | Ivabradine | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Moderate | 1 | [
[
[
1094,
24,
880
]
],
[
[
1094,
63,
1478
],
[
1478,
24,
880
]
],
[
[
1094,
24,
159
],
[
159,
63,
880
]
],
[
[
1094,
24,
951
],
[
951,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Lar... |
DB00530 | DB09039 | 1,195 | 1,670 | [
"DDInter667",
"DDInter629"
] | Erlotinib | Eliglustat | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Moderate | 1 | [
[
[
1195,
24,
1670
]
],
[
[
1195,
63,
839
],
[
839,
24,
1670
]
],
[
[
1195,
24,
943
],
[
943,
63,
1670
]
],
[
[
1195,
24,
478
],
[
478,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and S... |
DB09293 | DB11156 | 116 | 1,218 | [
"DDInter954",
"DDInter1546"
] | Iodide I-131 | Pyrantel | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation do... | Pyrantel is a pyrimidine-derivative anthelmintic agent for the oral treatment of various parasitic worm infections including ascariasis, hookworm infections, enterobiasis (pinworm infection), trichostrongyliasis, and trichinellosis . Pyrantel was initially described in 1965 by researchers from Pfizer who sought cyclic ... | Moderate | 1 | [
[
[
116,
24,
1218
]
],
[
[
116,
63,
516
],
[
516,
24,
1074
],
[
1074,
24,
1218
]
],
[
[
116,
24,
1004
],
[
1004,
63,
1074
],
[
1074,
24,... | [
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyrantel"
]
],
[
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
... | Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Pyr... |
DB00585 | DB00749 | 1,127 | 59 | [
"DDInter1309",
"DDInter699"
] | Nizatidine | Etodolac | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Minor | 0 | [
[
[
1127,
23,
59
]
],
[
[
1127,
7,
7720
],
[
7720,
45,
59
]
],
[
[
1127,
21,
29187
],
[
29187,
60,
59
]
],
[
[
1127,
1,
1194
],
[
1194,
... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etodolac"
]
],
[
[
"Nizatidine",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",... | Nizatidine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Etodolac (Compound)
Nizatidine (Compound) causes Rhinitis (Side Effect) and Rhinitis (Side Effect) is caused by Etodolac (Compound)
Nizatidine (Compound) resembles Ranitidine (Compound) and Ranitidine may cause a minor interaction that can limi... |
DB00014 | DB08875 | 521 | 1,618 | [
"DDInter839",
"DDInter262"
] | Goserelin | Cabozantinib | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
521,
25,
1618
]
],
[
[
521,
23,
112
],
[
112,
23,
1618
]
],
[
[
521,
24,
384
],
[
384,
63,
1618
]
],
[
[
521,
24,
480
],
[
480,
... | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idel... |
DB00687 | DB01320 | 870 | 651 | [
"DDInter747",
"DDInter783"
] | Fludrocortisone | Fosphenytoin | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
870,
24,
651
]
],
[
[
870,
23,
307
],
[
307,
1,
651
]
],
[
[
870,
63,
362
],
[
362,
1,
651
]
],
[
[
870,
24,
998
],
[
998,
1,
... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],... | Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Fosphenytoin (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Co... |
DB09100 | DB11348 | 320 | 1,065 | [
"DDInter1799",
"DDInter279"
] | Thyroid, porcine | Calcium Phosphate | Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyro... | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
320,
24,
1065
]
],
[
[
320,
63,
1231
],
[
1231,
24,
1065
]
],
[
[
320,
62,
417
],
[
417,
23,
17
],
[
17,
24,
1065
]
],
[
[
320,
... | [
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Thyroid, porcine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolevame... | Thyroid, porcine may cause a moderate interaction that could exacerbate diseases when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Thyroid, porcine may cause a minor interaction that can limit clinical effects when taken with Sucral... |
DB11601 | DB11767 | 1,270 | 1,583 | [
"DDInter1889",
"DDInter1643"
] | Tuberculin purified protein derivative | Sarilumab | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
1270,
24,
1583
]
],
[
[
1270,
63,
850
],
[
850,
24,
1583
]
],
[
[
1270,
24,
738
],
[
738,
63,
1583
]
],
[
[
1270,
63,
1064
],
[
1064,
... | [
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases w... | Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Tuberculin purified protein derivative may cause a moderate interac... |
DB00443 | DB11866 | 251 | 1,068 | [
"DDInter195",
"DDInter1618"
] | Betamethasone | Romosozumab | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
251,
24,
1068
]
],
[
[
251,
25,
770
],
[
770,
24,
1068
]
],
[
[
251,
40,
167
],
[
167,
24,
1068
]
],
[
[
251,
1,
1486
],
[
1486,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Betamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Th... | Betamethasone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Betamethasone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that cou... |
DB00468 | DB09080 | 1,424 | 144 | [
"DDInter1557",
"DDInter1331"
] | Quinine | Olodaterol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
1424,
24,
144
]
],
[
[
1424,
23,
1247
],
[
1247,
23,
144
]
],
[
[
1424,
24,
956
],
[
956,
24,
144
]
],
[
[
1424,
25,
1011
],
[
1011,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Quinine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Nor... |
DB00414 | DB00609 | 590 | 595 | [
"DDInter16",
"DDInter694"
] | Acetohexamide | Ethionamide | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Moderate | 1 | [
[
[
590,
24,
595
]
],
[
[
590,
63,
176
],
[
176,
24,
595
]
],
[
[
590,
24,
1254
],
[
1254,
63,
595
]
],
[
[
590,
24,
597
],
[
597,
2... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethionamide"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Ethionamide
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with In... |
DB00283 | DB12161 | 701 | 730 | [
"DDInter395",
"DDInter512"
] | Clemastine | Deutetrabenazine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
701,
24,
730
]
],
[
[
701,
24,
100
],
[
100,
24,
730
]
],
[
[
701,
35,
1242
],
[
1242,
24,
730
]
],
[
[
701,
24,
104
],
[
104,
2... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate intera... |
DB01227 | DB05812 | 1,301 | 1,374 | [
"DDInter1043",
"DDInter8"
] | Levacetylmethadol | Abiraterone | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
1301,
25,
1374
]
],
[
[
1301,
6,
8374
],
[
8374,
45,
1374
]
],
[
[
1301,
62,
112
],
[
112,
23,
1374
]
],
[
[
1301,
25,
760
],
[
760,
... | [
[
[
"Levacetylmethadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Levacetylmethadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Levacetylmethadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound)
Levacetylmethadol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Abiraterone
... |
DB01206 | DB10276 | 37 | 1,624 | [
"DDInter1086",
"DDInter1623"
] | Lomustine | Rotavirus vaccine | An alkylating agent of value against both hematologic malignancies and solid tumors. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotar... | Major | 2 | [
[
[
37,
25,
1624
]
],
[
[
37,
74,
552
],
[
552,
25,
1624
]
],
[
[
37,
63,
1307
],
[
1307,
25,
1624
]
],
[
[
37,
64,
770
],
[
770,
25... | [
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Lomustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Lomustine may cause a moderate interaction that could exacerbate... |
DB00969 | DB01319 | 2 | 34 | [
"DDInter52",
"DDInter777"
] | Alosetron | Fosamprenavir | Alosetron is a 5-HT3 antagonist used only for the management of severe diarrhoea-predominant irritable bowel syndrome (IBS) in women. Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. Alosetron was voluntarily withdrawn from the US marke... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
2,
24,
34
]
],
[
[
2,
63,
1091
],
[
1091,
40,
34
]
],
[
[
2,
6,
8374
],
[
8374,
45,
34
]
],
[
[
2,
21,
28835
],
[
28835,
60,
... | [
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Alosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Alosetron may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Alosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fosamprenavir (Compound)
Alosetron (Compound) causes Hyperglycaemia (Side Effect) and H... |
DB01156 | DB06701 | 593 | 1,177 | [
"DDInter252",
"DDInter521"
] | Bupropion | Dexmethylphenidate | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer s... | Major | 2 | [
[
[
593,
25,
1177
]
],
[
[
593,
64,
895
],
[
895,
1,
1177
]
],
[
[
593,
6,
7390
],
[
7390,
45,
1177
]
],
[
[
593,
21,
28702
],
[
28702,
... | [
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexmethylphenidate"
]
],
[
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylphenidate"
],
[
"Methylphenidat... | Bupropion may lead to a major life threatening interaction when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Bupropion (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Dexmethylphenidate (Compound)
Bupropion (Compound) causes Muscle twitching (Side Effect... |
DB06212 | DB11691 | 165 | 1,499 | [
"DDInter1833",
"DDInter1258"
] | Tolvaptan | Naldemedine | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
165,
24,
1499
]
],
[
[
165,
63,
723
],
[
723,
24,
1499
]
],
[
[
165,
24,
1670
],
[
1670,
24,
1499
]
],
[
[
165,
24,
1033
],
[
1033,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglus... |
DB00877 | DB01009 | 629 | 935 | [
"DDInter1678",
"DDInter1009"
] | Sirolimus | Ketoprofen | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Major | 2 | [
[
[
629,
25,
935
]
],
[
[
629,
64,
1274
],
[
1274,
24,
935
]
],
[
[
629,
25,
1263
],
[
1263,
1,
935
]
],
[
[
629,
64,
886
],
[
886,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketoprofen"
]
],
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u}... | Sirolimus may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Sirolimus may lead to a major life threatening interaction when taken with Bromfenac and Bromfenac (Compound) resembles Keto... |
DB00398 | DB00675 | 79 | 888 | [
"DDInter1702",
"DDInter1744"
] | Sorafenib | Tamoxifen | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
79,
24,
888
]
],
[
[
79,
24,
675
],
[
675,
25,
888
]
],
[
[
79,
24,
543
],
[
543,
63,
888
]
],
[
[
79,
6,
4973
],
[
4973,
45,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Tamoxifen
Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperami... |
DB00104 | DB09351 | 966 | 722 | [
"DDInter1323",
"DDInter1048"
] | Octreotide | Levobetaxolol (ophthalmic) | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Moderate | 1 | [
[
[
966,
24,
722
]
],
[
[
966,
40,
1154
],
[
1154,
24,
722
]
],
[
[
966,
24,
699
],
[
699,
62,
27
],
[
27,
23,
722
]
],
[
[
966,
40,... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a mo... | Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Octreotide (Compound) resembles Pasireotide (Compound) and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Octreotide may cause a moderate interaction that c... |
DB00741 | DB06186 | 167 | 1,439 | [
"DDInter885",
"DDInter969"
] | Hydrocortisone | Ipilimumab | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
167,
24,
1439
]
],
[
[
167,
1,
617
],
[
617,
24,
1439
]
],
[
[
167,
24,
1412
],
[
1412,
63,
1439
]
],
[
[
167,
63,
1560
],
[
1560,
... | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a... | Hydrocortisone (Compound) resembles Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol and Calaspargase pegol may cause a moderat... |
DB00397 | DB00902 | 1,466 | 104 | [
"DDInter1458",
"DDInter1168"
] | Phenylpropanolamine | Methdilazine | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1466,
24,
104
]
],
[
[
1466,
24,
820
],
[
820,
1,
104
]
],
[
[
1466,
24,
401
],
[
401,
63,
104
]
],
[
[
1466,
24,
1503
],
[
1503,
... | [
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Phenylpropanolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimema... | Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Phenylpropanolamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moder... |
DB00095 | DB11817 | 66 | 1,259 | [
"DDInter623",
"DDInter165"
] | Efalizumab | Baricitinib | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
66,
25,
1259
]
],
[
[
66,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
66,
24,
949
],
[
949,
24,
1259
]
],
[
[
66,
24,
1129
],
[
1129,
... | [
[
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium teta... |
DB00758 | DB14881 | 1,347 | 180 | [
"DDInter413",
"DDInter1329"
] | Clopidogrel | Oliceridine | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
1347,
24,
180
]
],
[
[
1347,
24,
578
],
[
578,
24,
180
]
],
[
[
1347,
63,
752
],
[
752,
24,
180
]
],
[
[
1347,
62,
888
],
[
888,
... | [
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[... | Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cim... |
DB00472 | DB06595 | 758 | 1,491 | [
"DDInter758",
"DDInter1214"
] | Fluoxetine | Midostaurin | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Moderate | 1 | [
[
[
758,
24,
1491
]
],
[
[
758,
23,
112
],
[
112,
23,
1491
]
],
[
[
758,
25,
888
],
[
888,
24,
1491
]
],
[
[
758,
24,
1017
],
[
1017,
... | [
[
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Fluoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Fluoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Fluoxetine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause... |
DB00620 | DB14740 | 175 | 771 | [
"DDInter1855",
"DDInter881"
] | Triamcinolone | Hyaluronidase | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939. Early research into hyaluronidase identified it as a "spreading factor" which allowed for increased permea... | Minor | 0 | [
[
[
175,
23,
771
]
],
[
[
175,
24,
1438
],
[
1438,
23,
771
]
],
[
[
175,
40,
167
],
[
167,
23,
771
]
],
[
[
175,
1,
617
],
[
617,
23... | [
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Triamcinolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a minor interaction ... |
DB06335 | DB11979 | 761 | 1,320 | [
"DDInter1646",
"DDInter625"
] | Saxagliptin | Elagolix | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
761,
24,
1320
]
],
[
[
761,
63,
168
],
[
168,
23,
1320
]
],
[
[
761,
63,
1249
],
[
1249,
24,
1320
]
],
[
[
761,
24,
129
],
[
129,
... | [
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Nafcillin and Nafcillin... |
DB01255 | DB01364 | 633 | 22 | [
"DDInter1078",
"DDInter650"
] | Lisdexamfetamine | Ephedrine | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
633,
24,
22
]
],
[
[
633,
1,
80
],
[
80,
24,
22
]
],
[
[
633,
40,
1529
],
[
1529,
63,
22
]
],
[
[
633,
63,
1445
],
[
1445,
1,
... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} may ca... | Lisdexamfetamine (Compound) resembles Amphetamine (Compound) and Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine
Lisdexamfetamine (Compound) resembles Metamfetamine (Compound) and Metamfetamine may cause a moderate interaction that could exacerbate diseases when tak... |
DB10429 | DB12267 | 200 | 1,476 | [
"DDInter282",
"DDInter233"
] | Candida albicans | Brigatinib | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
200,
24,
1476
]
],
[
[
200,
63,
168
],
[
168,
23,
1476
]
],
[
[
200,
63,
629
],
[
629,
24,
1476
]
],
[
[
200,
24,
1456
],
[
1456,
... | [
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
... | Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus a... |
DB00609 | DB00912 | 595 | 473 | [
"DDInter694",
"DDInter1581"
] | Ethionamide | Repaglinide | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Moderate | 1 | [
[
[
595,
24,
473
]
],
[
[
595,
21,
28757
],
[
28757,
60,
473
]
],
[
[
595,
24,
1487
],
[
1487,
63,
473
]
],
[
[
595,
63,
168
],
[
168,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
]
],
[
[
"Ethionamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is c... | Ethionamide (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Repaglinide (Compound)
Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when... |
DB01240 | DB08907 | 885 | 1,344 | [
"DDInter657",
"DDInter280"
] | Epoprostenol | Canagliflozin | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
885,
24,
1344
]
],
[
[
885,
24,
549
],
[
549,
1,
1344
]
],
[
[
885,
21,
28962
],
[
28962,
60,
1344
]
],
[
[
885,
63,
1445
],
[
1445,
... | [
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Epoprostenol (Compound) causes Hyperkalaemia (Side Effect) and Hyperkalaemia (Side Effect) is caused by Canagliflozin (Compound)
Epoprostenol may cau... |
DB00065 | DB00853 | 581 | 1,686 | [
"DDInter923",
"DDInter1762"
] | Infliximab | Temozolomide | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Major | 2 | [
[
[
581,
25,
1686
]
],
[
[
581,
25,
970
],
[
970,
24,
1686
]
],
[
[
581,
25,
1330
],
[
1330,
63,
1686
]
],
[
[
581,
24,
496
],
[
496,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Temozolomide"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
... | Infliximab may lead to a major life threatening interaction when taken with Fluorouracil and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide
Infliximab may lead to a major life threatening interaction when taken with Naxitamab and Naxitamab may cause a moderate ... |
DB01097 | DB11791 | 1,377 | 785 | [
"DDInter1033",
"DDInter287"
] | Leflunomide | Capmatinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Major | 2 | [
[
[
1377,
25,
785
]
],
[
[
1377,
64,
1324
],
[
1324,
24,
785
]
],
[
[
1377,
25,
868
],
[
868,
24,
785
]
],
[
[
1377,
25,
1320
],
[
1320,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
... | Leflunomide may lead to a major life threatening interaction when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Leflunomide may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moder... |
DB00619 | DB15328 | 1,419 | 829 | [
"DDInter909",
"DDInter1896"
] | Imatinib | Ubrogepant | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1419,
24,
829
]
],
[
[
1419,
25,
1476
],
[
1476,
24,
829
]
],
[
[
1419,
35,
1468
],
[
1468,
24,
829
]
],
[
[
1419,
24,
578
],
[
578,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
... | Imatinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases w... |
DB01105 | DB01149 | 222 | 851 | [
"DDInter1665",
"DDInter1274"
] | Sibutramine | Nefazodone | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
222,
25,
851
]
],
[
[
222,
63,
252
],
[
252,
40,
851
]
],
[
[
222,
63,
1178
],
[
1178,
1,
851
]
],
[
[
222,
24,
673
],
[
673,
40... | [
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxy... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodo... |
DB01246 | DB09080 | 820 | 144 | [
"DDInter45",
"DDInter1331"
] | Alimemazine | Olodaterol | A phenothiazine derivative that is used as an antipruritic. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
820,
24,
144
]
],
[
[
820,
62,
1247
],
[
1247,
23,
144
]
],
[
[
820,
63,
956
],
[
956,
24,
144
]
],
[
[
820,
25,
1011
],
[
1011,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Olodaterol
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin... |
DB00945 | DB09278 | 1,479 | 852 | [
"DDInter20",
"DDInter24"
] | Acetylsalicylic acid | Activated charcoal | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity... | Moderate | 1 | [
[
[
1479,
24,
852
]
],
[
[
1479,
24,
1411
],
[
1411,
24,
852
]
],
[
[
1479,
63,
556
],
[
556,
24,
852
]
],
[
[
1479,
25,
1377
],
[
1377,
... | [
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when ta... |
DB00242 | DB14962 | 1,064 | 1,363 | [
"DDInter392",
"DDInter1847"
] | Cladribine | Trastuzumab deruxtecan | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes i... | Major | 2 | [
[
[
1064,
25,
1363
]
],
[
[
1064,
25,
1430
],
[
1430,
24,
1363
]
],
[
[
1064,
63,
1253
],
[
1253,
24,
1363
]
],
[
[
1064,
64,
440
],
[
440... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab deruxtecan"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-... | Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab deruxtecan
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palif... |
DB01097 | DB09331 | 1,377 | 745 | [
"DDInter1033",
"DDInter478"
] | Leflunomide | Daratumumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Major | 2 | [
[
[
1377,
25,
745
]
],
[
[
1377,
64,
139
],
[
139,
24,
745
]
],
[
[
1377,
25,
4
],
[
4,
24,
745
]
],
[
[
1377,
63,
597
],
[
597,
24,... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daratumumab"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u... | Leflunomide may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Leflunomide may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesu... |
DB01281 | DB14711 | 881 | 779 | [
"DDInter5",
"DDInter1680"
] | Abatacept | Smallpox (Vaccinia) Vaccine, Live | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
881,
25,
779
]
],
[
[
881,
64,
1064
],
[
1064,
25,
779
]
],
[
[
881,
25,
1259
],
[
1259,
25,
779
]
],
[
[
881,
24,
270
],
[
270,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Clad... | Abatacept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Abatacept may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a maj... |
DB04868 | DB12887 | 478 | 1,598 | [
"DDInter1293",
"DDInter1750"
] | Nilotinib | Tazemetostat | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
478,
24,
1598
]
],
[
[
478,
63,
168
],
[
168,
23,
1598
]
],
[
[
478,
24,
594
],
[
594,
24,
1598
]
],
[
[
478,
25,
985
],
[
985,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib... |
DB00365 | DB13749 | 839 | 1,473 | [
"DDInter842",
"DDInter1116"
] | Grepafloxacin | Magnesium gluconate | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts and is used as a mineral supplement. Magnesium is ubiquitous in the human body, and is naturally present in many foods, added to other food products, available as a dietary supplement and used as an... | Moderate | 1 | [
[
[
839,
24,
1473
]
],
[
[
839,
24,
544
],
[
544,
24,
1473
]
],
[
[
839,
24,
544
],
[
544,
24,
1299
],
[
1299,
24,
1473
]
],
[
[
839,
... | [
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
]
],
[
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium su... | Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate
Grepafloxacin may cause a moderate interaction that could exacerbate diseases when tak... |
DB01211 | DB08865 | 609 | 1,593 | [
"DDInter393",
"DDInter448"
] | Clarithromycin | Crizotinib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
609,
25,
1593
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
609,
18,
2942
],
[
2942,
46,
1593
]
],
[
[
609,
7,
5409
],
[
5409,
... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Clarithromycin (Compound) downregulates KEAP1 (Gene) and KEAP1 (Gene) is upregulated by Crizotinib (Compound)
Clarithromycin (Compound) upregulates SOCS2 (Gene) and SOCS2 (Gene) is upregulated by Crizotinib (Compound)
Clar... |
DB01229 | DB12240 | 973 | 110 | [
"DDInter1378",
"DDInter1485"
] | Paclitaxel (protein-bound) | Polatuzumab vedotin | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
973,
24,
110
]
],
[
[
973,
24,
129
],
[
129,
23,
110
]
],
[
[
973,
63,
467
],
[
467,
24,
110
]
],
[
[
973,
24,
980
],
[
980,
24,... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Polatuzuma... |
DB00748 | DB00782 | 662 | 1,123 | [
"DDInter297",
"DDInter1535"
] | Carbinoxamine | Propantheline | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
662,
24,
1123
]
],
[
[
662,
18,
8582
],
[
8582,
57,
1123
]
],
[
[
662,
21,
28898
],
[
28898,
60,
1123
]
],
[
[
662,
24,
551
],
[
551,
... | [
[
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Carbinoxamine",
"{u} (Compound) downregulates {v} (Gene)",
"PLEKHM1"
],
[
"PLEKHM1",
"{u} (Gene) is downre... | Carbinoxamine (Compound) downregulates PLEKHM1 (Gene) and PLEKHM1 (Gene) is downregulated by Propantheline (Compound)
Carbinoxamine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propantheline (Compound)
Carbinoxamine may cause a moderate interaction that could exacerbate disea... |
DB00242 | DB00294 | 1,064 | 1,336 | [
"DDInter392",
"DDInter701"
] | Cladribine | Etonogestrel | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Moderate | 1 | [
[
[
1064,
24,
1336
]
],
[
[
1064,
24,
566
],
[
566,
1,
1336
]
],
[
[
1064,
24,
873
],
[
873,
40,
1336
]
],
[
[
1064,
21,
29221
],
[
29221,... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levonorgestrel"
],
... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Levonorgestrel and Levonorgestrel (Compound) resembles Etonogestrel (Compound)
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Norgestimate and Norgestimate (Compound) resembles Etonoges... |
DB00988 | DB09045 | 817 | 52 | [
"DDInter584",
"DDInter607"
] | Dopamine | Dulaglutide | One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA... | Moderate | 1 | [
[
[
817,
24,
52
]
],
[
[
817,
24,
170
],
[
170,
23,
52
]
],
[
[
817,
63,
73
],
[
73,
24,
52
]
],
[
[
817,
40,
532
],
[
532,
24,
... | [
[
[
"Dopamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Dopamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
... | Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Dopamine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phenterm... |
DB00295 | DB06702 | 475 | 573 | [
"DDInter1244",
"DDInter731"
] | Morphine | Fesoterodine | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
475,
24,
573
]
],
[
[
475,
24,
211
],
[
211,
1,
573
]
],
[
[
475,
6,
12523
],
[
12523,
45,
573
]
],
[
[
475,
21,
28681
],
[
28681,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
... | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Morphine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Morphine (Compound) causes Hypersensitivity (Side Effect) and Hy... |
DB00762 | DB11730 | 613 | 351 | [
"DDInter973",
"DDInter1588"
] | Irinotecan | Ribociclib | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Moderate | 1 | [
[
[
613,
24,
351
]
],
[
[
613,
24,
466
],
[
466,
62,
351
]
],
[
[
613,
63,
288
],
[
288,
24,
351
]
],
[
[
613,
24,
987
],
[
987,
63,... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Butalbital and Buta... |
DB00361 | DB01045 | 134 | 463 | [
"DDInter1939",
"DDInter1590"
] | Vinorelbine | Rifampicin | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
134,
24,
463
]
],
[
[
134,
24,
690
],
[
690,
40,
463
]
],
[
[
134,
7,
8155
],
[
8155,
45,
463
]
],
[
[
134,
6,
4973
],
[
4973,
4... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
[
... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Vinorelbine (Compound) upregulates ABCC5 (Gene) and ABCC5 (Gene) is bound by Rifampicin (Compound)
Vinorelbine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is ... |
DB09048 | DB12941 | 555 | 466 | [
"DDInter1284",
"DDInter481"
] | Netupitant | Darolutamide | Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug i... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
555,
23,
466
]
],
[
[
555,
23,
283
],
[
283,
23,
466
]
],
[
[
555,
25,
484
],
[
484,
23,
466
]
],
[
[
555,
63,
723
],
[
723,
23,... | [
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
... | Netupitant may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Netupitant may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause ... |
DB00424 | DB01193 | 19 | 819 | [
"DDInter896",
"DDInter12"
] | Hyoscyamine | Acebutolol | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
19,
24,
819
]
],
[
[
19,
24,
887
],
[
887,
1,
819
]
],
[
[
19,
63,
88
],
[
88,
1,
819
]
],
[
[
19,
21,
28762
],
[
28762,
60,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Acebutolol (Compound)
Hy... |
DB00086 | DB11793 | 1,167 | 738 | [
"DDInter1712",
"DDInter1297"
] | Streptokinase | Niraparib | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1167,
24,
738
]
],
[
[
1167,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1167,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1167,
24,
848
],
[
848,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasati... | Streptokinase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Streptokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate int... |
DB01309 | DB12267 | 1,254 | 1,476 | [
"DDInter933",
"DDInter233"
] | Insulin glulisine | Brigatinib | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1254,
24,
1476
]
],
[
[
1254,
63,
1206
],
[
1206,
23,
1476
]
],
[
[
1254,
63,
629
],
[
629,
24,
1476
]
],
[
[
1254,
24,
1385
],
[
1385... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gemfibrozil"
... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Gemfibrozil and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sirolim... |
DB00635 | DB01149 | 1,573 | 851 | [
"DDInter1515",
"DDInter1274"
] | Prednisone | Nefazodone | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
1573,
24,
851
]
],
[
[
1573,
6,
8374
],
[
8374,
45,
851
]
],
[
[
1573,
21,
29477
],
[
29477,
60,
851
]
],
[
[
1573,
63,
1101
],
[
1101... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Prednisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Prednisone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Prednisone (Compound) causes Hypercholesterolaemia (Side Effect) and Hypercholesterolaemia (Side Effect) is caused by Nefazodone (Compound)
Prednisone may cause a moderate interaction that could exacerbate diseases when taken ... |
DB04855 | DB06605 | 540 | 1,409 | [
"DDInter602",
"DDInter108"
] | Dronedarone | Apixaban | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Moderate | 1 | [
[
[
540,
24,
1409
]
],
[
[
540,
6,
4973
],
[
4973,
45,
1409
]
],
[
[
540,
21,
28787
],
[
28787,
60,
1409
]
],
[
[
540,
25,
1670
],
[
1670,... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
]
],
[
[
"Dronedarone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Dronedarone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Apixaban (Compound)
Dronedarone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Apixaban (Compound)
Dronedarone may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may cause... |
DB01255 | DB06723 | 633 | 115 | [
"DDInter1078",
"DDInter58"
] | Lisdexamfetamine | Aluminum hydroxide | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. | Moderate | 1 | [
[
[
633,
24,
115
]
],
[
[
633,
21,
28882
],
[
28882,
60,
115
]
],
[
[
633,
1,
1523
],
[
1523,
23,
115
]
],
[
[
633,
63,
355
],
[
355,
... | [
[
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
]
],
[
[
"Lisdexamfetamine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body te... | Lisdexamfetamine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Aluminum hydroxide (Compound)
Lisdexamfetamine (Compound) resembles Labetalol (Compound) and Labetalol may cause a minor interaction that can limit clinical effects when taken with Alumi... |
DB01324 | DB06292 | 178 | 549 | [
"DDInter1490",
"DDInter474"
] | Polythiazide | Dapagliflozin | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p826) | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
178,
24,
549
]
],
[
[
178,
24,
1344
],
[
1344,
40,
549
]
],
[
[
178,
21,
28898
],
[
28898,
60,
549
]
],
[
[
178,
63,
1179
],
[
1179,
... | [
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Polythiazide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Dapagliflozin (Compound)
Polythiazide may cause... |
DB00424 | DB00726 | 19 | 1,164 | [
"DDInter896",
"DDInter1876"
] | Hyoscyamine | Trimipramine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
19,
24,
1164
]
],
[
[
19,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
19,
63,
508
],
[
508,
40,
1164
]
],
[
[
19,
21,
28809
],
[
28809,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Trimipramine (Co... |
DB01181 | DB01235 | 1,532 | 1,191 | [
"DDInter906",
"DDInter1054"
] | Ifosfamide | Levodopa | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
1532,
24,
1191
]
],
[
[
1532,
63,
1307
],
[
1307,
40,
1191
]
],
[
[
1532,
24,
871
],
[
871,
40,
1191
]
],
[
[
1532,
21,
28936
],
[
289... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan and Oxitriptan (Compound) resembles Levodopa (Compound)
Ifosfa... |
DB01097 | DB06168 | 1,377 | 1,531 | [
"DDInter1033",
"DDInter281"
] | Leflunomide | Canakinumab | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Major | 2 | [
[
[
1377,
25,
1531
]
],
[
[
1377,
23,
1193
],
[
1193,
62,
1531
]
],
[
[
1377,
62,
1461
],
[
1461,
23,
1531
]
],
[
[
1377,
25,
1644
],
[
16... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
]
],
[
[
"Leflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Leflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Leflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vi... |
DB00530 | DB09054 | 1,195 | 384 | [
"DDInter667",
"DDInter905"
] | Erlotinib | Idelalisib | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1195,
24,
384
]
],
[
[
1195,
24,
1627
],
[
1627,
62,
384
]
],
[
[
1195,
24,
555
],
[
555,
23,
384
]
],
[
[
1195,
23,
307
],
[
307,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupita... |
DB00552 | DB10343 | 1,238 | 962 | [
"DDInter1425",
"DDInter160"
] | Pentostatin | Bacillus calmette-guerin substrain tice live antigen | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1238,
25,
962
]
],
[
[
1238,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1238,
24,
270
],
[
270,
64,
962
]
],
[
[
1238,
25,
1488
],
[
1488,
... | [
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Pentostatin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Ocreliz... |
DB00258 | DB00381 | 666 | 376 | [
"DDInter270",
"DDInter79"
] | Calcium acetate | Amlodipine | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called _dihydropyridine calcium channel blockers_. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial... | Moderate | 1 | [
[
[
666,
24,
376
]
],
[
[
666,
24,
1428
],
[
1428,
1,
376
]
],
[
[
666,
24,
1081
],
[
1081,
40,
376
]
],
[
[
666,
21,
28658
],
[
28658,
... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amlodipine"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isradipine"
]... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Isradipine and Isradipine (Compound) resembles Amlodipine (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Nicardipine and Nicardipine (Compound) resembles Amlodipine... |
DB00394 | DB01021 | 218 | 674 | [
"DDInter168",
"DDInter1861"
] | Beclomethasone dipropionate | Trichlormethiazide | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Bec... | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Moderate | 1 | [
[
[
218,
24,
674
]
],
[
[
218,
24,
1014
],
[
1014,
40,
674
]
],
[
[
218,
24,
178
],
[
178,
1,
674
]
],
[
[
218,
7,
4759
],
[
4759,
4... | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trichlormethiazide"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken wit... | Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Benzthiazide and Benzthiazide (Compound) resembles Trichlormethiazide (Compound)
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polyth... |
DB00582 | DB01234 | 1,622 | 1,220 | [
"DDInter1946",
"DDInter513"
] | Voriconazole | Dexamethasone | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1622,
24,
1220
]
],
[
[
1622,
24,
870
],
[
870,
1,
1220
]
],
[
[
1622,
25,
175
],
[
175,
40,
1220
]
],
[
[
1622,
63,
1351
],
[
1351,
... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
... | Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Voriconazole may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone ... |
DB00350 | DB01143 | 1,214 | 923 | [
"DDInter1226",
"DDInter65"
] | Minoxidil | Amifostine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
1214,
24,
923
]
],
[
[
1214,
24,
572
],
[
572,
24,
923
]
],
[
[
1214,
64,
1000
],
[
1000,
24,
923
]
],
[
[
1214,
24,
1084
],
[
1084,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenoldopam"
],
[
... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Fenoldopam and Fenoldopam may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Minoxidil may lead to a major life threatening interaction when taken with Guanadrel and Guanadrel may cause a mo... |
DB06788 | DB08907 | 1,616 | 1,344 | [
"DDInter864",
"DDInter280"
] | Histrelin | Canagliflozin | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1616,
24,
1344
]
],
[
[
1616,
63,
549
],
[
549,
1,
1344
]
],
[
[
1616,
63,
739
],
[
739,
24,
1344
]
],
[
[
1616,
64,
1327
],
[
1327,
... | [
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Lomefloxacin and Lomefloxacin may cause a moderate interaction... |
DB01041 | DB12834 | 770 | 148 | [
"DDInter1789",
"DDInter1649"
] | Thalidomide | Secnidazole | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Secnidazole is a second-generation 5-nitroimidazole antimicrobial agent. It is structurally related to other 5-nitroimidazoles, including and , but displays improved oral absorption and a longer terminal elimination half-life than other drugs in this class. Secnidazole is selective against many anaerobic Gram-positive ... | Moderate | 1 | [
[
[
770,
24,
148
]
],
[
[
770,
24,
1593
],
[
1593,
24,
148
]
],
[
[
770,
63,
597
],
[
597,
24,
148
]
],
[
[
770,
64,
1555
],
[
1555,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secnidazole"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol an... |
DB09134 | DB14600 | 1,552 | 224 | [
"DDInter966",
"DDInter620"
] | Ioversol | Edetate disodium anhydrous | Ioversol is a non-ionic compound with a tri-iodinated benzene ring used as a contrast dye in diagnostic procedures to visualize different types of organs and tissues. Iodine has a high atomic density, which gives it the ability to attenuate X-rays. The intravascular administration of iodine compounds, such as ioversol,... | Edetate disodium anhydrous is a polyvalent chelating agent used to treat hypercalcemia and digitalis toxicity associated ventricular arrhythmias. | Major | 2 | [
[
[
1552,
25,
224
]
],
[
[
1552,
64,
372
],
[
372,
24,
224
]
],
[
[
1552,
64,
789
],
[
789,
24,
372
],
[
372,
24,
224
]
],
[
[
1552,
... | [
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edetate disodium anhydrous"
]
],
[
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofarabine"... | Ioversol may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Edetate disodium anhydrous
Ioversol may lead to a major life threatening interaction when taken with Foscarnet and Foscarnet may cause a m... |
DB00331 | DB01319 | 1,645 | 34 | [
"DDInter1164",
"DDInter777"
] | Metformin | Fosamprenavir | Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.[L12207,A176173] Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "i... | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Moderate | 1 | [
[
[
1645,
24,
34
]
],
[
[
1645,
24,
1091
],
[
1091,
40,
34
]
],
[
[
1645,
21,
29062
],
[
29062,
60,
34
]
],
[
[
1645,
24,
609
],
[
609,
... | [
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
]
],
[
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
],
[
... | Metformin may cause a moderate interaction that could exacerbate diseases when taken with Amprenavir and Amprenavir (Compound) resembles Fosamprenavir (Compound)
Metformin (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Fosamprenavir (Compound)
Metformin may cause a moderate inter... |
DB00281 | DB00705 | 608 | 441 | [
"DDInter1066",
"DDInter496"
] | Lidocaine | Delavirdine | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Moderate | 1 | [
[
[
608,
24,
441
]
],
[
[
608,
6,
21998
],
[
21998,
45,
441
]
],
[
[
608,
21,
29323
],
[
29323,
60,
441
]
],
[
[
608,
23,
868
],
[
868,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7-CYP3A51P"
],
[
"CYP3A7-CYP3A51P",
"{u} (Gene) is bound by... | Lidocaine (Compound) binds CYP3A7-CYP3A51P (Gene) and CYP3A7-CYP3A51P (Gene) is bound by Delavirdine (Compound)
Lidocaine (Compound) causes Paralysis (Side Effect) and Paralysis (Side Effect) is caused by Delavirdine (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemu... |
DB00959 | DB01764 | 1,486 | 805 | [
"DDInter1191",
"DDInter469"
] | Methylprednisolone | Dalfopristin | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome ... | Moderate | 1 | [
[
[
1486,
24,
805
]
],
[
[
1486,
6,
8374
],
[
8374,
45,
805
]
],
[
[
1486,
63,
1101
],
[
1101,
23,
805
]
],
[
[
1486,
24,
283
],
[
283,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalfopristin"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound b... | Methylprednisolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dalfopristin (Compound)
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dalfopristin
... |
DB00224 | DB01611 | 215 | 1,487 | [
"DDInter917",
"DDInter893"
] | Indinavir | Hydroxychloroquine | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
215,
24,
1487
]
],
[
[
215,
6,
12523
],
[
12523,
45,
1487
]
],
[
[
215,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
215,
24,
723
],
[
723,... | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compo... | Indinavir (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxychloroquine (Compound)
Indinavir (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Aprepita... |
DB00440 | DB09280 | 1,548 | 1,604 | [
"DDInter1874",
"DDInter1101"
] | Trimethoprim | Lumacaftor | Trimethoprim is an antifolate antibacterial agent that inhibits bacterial dihydrofolate reductase (DHFR), a critical enzyme that catalyzes the formation of tetrahydrofolic acid (THF) - in doing so, it prevents the synthesis of bacterial DNA and ultimately continued bacterial survival. Trimethoprim is often used in comb... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
1548,
24,
1604
]
],
[
[
1548,
63,
1061
],
[
1061,
24,
1604
]
],
[
[
1548,
24,
473
],
[
473,
24,
1604
]
],
[
[
1548,
63,
1061
],
[
1061... | [
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Trimethoprim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
... | Trimethoprim may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Trimethoprim may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide a... |
DB00067 | DB09330 | 317 | 985 | [
"DDInter1921",
"DDInter1352"
] | Vasopressin | Osimertinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the ... | Major | 2 | [
[
[
317,
25,
985
]
],
[
[
317,
23,
112
],
[
112,
23,
985
]
],
[
[
317,
24,
134
],
[
134,
24,
985
]
],
[
[
317,
24,
1383
],
[
1383,
6... | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and ... |
DB00063 | DB06605 | 366 | 1,409 | [
"DDInter659",
"DDInter108"
] | Eptifibatide | Apixaban | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Major | 2 | [
[
[
366,
25,
1409
]
],
[
[
366,
23,
539
],
[
539,
62,
1409
]
],
[
[
366,
24,
109
],
[
109,
24,
1409
]
],
[
[
366,
24,
41
],
[
41,
63... | [
[
[
"Eptifibatide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
]
],
[
[
"Eptifibatide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
"Capsicum",
... | Eptifibatide may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Apixaban
Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine m... |
DB01105 | DB06810 | 222 | 397 | [
"DDInter1665",
"DDInter1484"
] | Sibutramine | Plicamycin | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
222,
24,
397
]
],
[
[
222,
24,
885
],
[
885,
24,
397
]
],
[
[
222,
63,
1061
],
[
1061,
24,
397
]
],
[
[
222,
25,
1237
],
[
1237,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil an... |
DB14723 | DB15822 | 159 | 69 | [
"DDInter1026",
"DDInter1504"
] | Larotrectinib | Pralsetinib | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Moderate | 1 | [
[
[
159,
24,
69
]
],
[
[
159,
63,
283
],
[
283,
24,
69
]
],
[
[
159,
64,
609
],
[
609,
25,
69
]
],
[
[
159,
63,
283
],
[
283,
63,
... | [
[
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pralsetinib"
]
],
[
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
... | Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Larotrectinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithrom... |
DB00060 | DB08889 | 912 | 350 | [
"DDInter947",
"DDInter299"
] | Interferon beta-1a | Carfilzomib | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
912,
24,
350
]
],
[
[
912,
24,
482
],
[
482,
24,
350
]
],
[
[
912,
24,
996
],
[
996,
63,
350
]
],
[
[
912,
63,
1451
],
[
1451,
2... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Beda... |
DB00477 | DB01168 | 216 | 1,053 | [
"DDInter363",
"DDInter1526"
] | Chlorpromazine | Procarbazine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Moderate | 1 | [
[
[
216,
24,
1053
]
],
[
[
216,
18,
4930
],
[
4930,
57,
1053
]
],
[
[
216,
21,
29119
],
[
29119,
60,
1053
]
],
[
[
216,
24,
480
],
[
480,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated... | Chlorpromazine (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Procarbazine (Compound)
Chlorpromazine (Compound) causes Haemolytic anaemia (Side Effect) and Haemolytic anaemia (Side Effect) is caused by Procarbazine (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate ... |
DB00865 | DB00938 | 939 | 455 | [
"DDInter187",
"DDInter1635"
] | Benzphetamine | Salmeterol | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Moderate | 1 | [
[
[
939,
24,
455
]
],
[
[
939,
24,
688
],
[
688,
63,
455
]
],
[
[
939,
40,
371
],
[
371,
63,
455
]
],
[
[
939,
6,
8374
],
[
8374,
45... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Benzphetamine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction th... |
DB00242 | DB11714 | 1,064 | 1,316 | [
"DDInter392",
"DDInter610"
] | Cladribine | Durvalumab | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Major | 2 | [
[
[
1064,
25,
1316
]
],
[
[
1064,
63,
1461
],
[
1461,
23,
1316
]
],
[
[
1064,
25,
167
],
[
167,
24,
1316
]
],
[
[
1064,
24,
200
],
[
200,
... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Durvalumab"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",... | Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Cladribine may lead to a major life threatening interaction when taken with Hydrocortisone and Hydrocortisone may ca... |
DB00976 | DB12332 | 1,056 | 1,619 | [
"DDInter1758",
"DDInter1626"
] | Telithromycin | Rucaparib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1056,
24,
1619
]
],
[
[
1056,
24,
222
],
[
222,
23,
1619
]
],
[
[
1056,
62,
112
],
[
112,
23,
1619
]
],
[
[
1056,
25,
1135
],
[
1135,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB08871 | DB09115 | 36 | 505 | [
"DDInter666",
"DDInter559"
] | Eribulin | Diiodohydroxyquinoline | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products. | Moderate | 1 | [
[
[
36,
24,
505
]
],
[
[
36,
64,
1593
],
[
1593,
24,
505
]
],
[
[
36,
63,
467
],
[
467,
24,
505
]
],
[
[
36,
25,
1510
],
[
1510,
24,... | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diiodohydroxyquinoline"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Cr... | Eribulin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin ... |
DB00834 | DB05773 | 932 | 1,047 | [
"DDInter1215",
"DDInter1848"
] | Mifepristone | Trastuzumab emtansine | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
932,
24,
1047
]
],
[
[
932,
24,
848
],
[
848,
24,
1047
]
],
[
[
932,
24,
310
],
[
310,
63,
1047
]
],
[
[
932,
64,
467
],
[
467,
... | [
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
... | Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Cabazita... |
DB00444 | DB09570 | 63 | 1,480 | [
"DDInter1765",
"DDInter1002"
] | Teniposide | Ixazomib | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Ixazomib a second generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortez... | Moderate | 1 | [
[
[
63,
24,
1480
]
],
[
[
63,
24,
987
],
[
987,
63,
1480
]
],
[
[
63,
63,
440
],
[
440,
24,
1480
]
],
[
[
63,
24,
453
],
[
453,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR s... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib
Teniposide may cause a moderate interact... |
DB14004 | DB14711 | 398 | 779 | [
"DDInter1806",
"DDInter1680"
] | Tildrakizumab | Smallpox (Vaccinia) Vaccine, Live | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasi... | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
398,
25,
779
]
],
[
[
398,
64,
1064
],
[
1064,
25,
779
]
],
[
[
398,
63,
147
],
[
147,
25,
779
]
],
[
[
398,
25,
676
],
[
676,
6... | [
[
[
"Tildrakizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Tildrakizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
... | Tildrakizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinbla... |
DB00976 | DB11760 | 1,056 | 119 | [
"DDInter1758",
"DDInter1742"
] | Telithromycin | Talazoparib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1056,
24,
119
]
],
[
[
1056,
25,
985
],
[
985,
24,
119
]
],
[
[
1056,
25,
1406
],
[
1406,
63,
119
]
],
[
[
1056,
24,
292
],
[
292,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Os... | Telithromycin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Telithromycin may lead to a major life threatening interaction when taken with Neratinib and Neratinib may cause a modera... |
DB06655 | DB08869 | 5 | 162 | [
"DDInter1077",
"DDInter1773"
] | Liraglutide | Tesamorelin | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and... | Moderate | 1 | [
[
[
5,
24,
162
]
],
[
[
5,
63,
245
],
[
245,
24,
162
]
],
[
[
5,
24,
1296
],
[
1296,
63,
162
]
],
[
[
5,
63,
245
],
[
245,
24,
... | [
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tesamorelin"
]
],
[
[
"Liraglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Tesamorelin
Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec... |
DB12267 | DB12825 | 1,476 | 1,375 | [
"DDInter233",
"DDInter1032"
] | Brigatinib | Lefamulin | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1476,
24,
1375
]
],
[
[
1476,
24,
159
],
[
159,
63,
1375
]
],
[
[
1476,
63,
309
],
[
309,
24,
1375
]
],
[
[
1476,
64,
976
],
[
976,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and ... |
DB00067 | DB09078 | 317 | 1,228 | [
"DDInter1921",
"DDInter1036"
] | Vasopressin | Lenvatinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
317,
24,
1228
]
],
[
[
317,
23,
112
],
[
112,
23,
1228
]
],
[
[
317,
24,
609
],
[
609,
24,
1228
]
],
[
[
317,
24,
927
],
[
927,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin an... |
DB00443 | DB00575 | 251 | 1,020 | [
"DDInter195",
"DDInter412"
] | Betamethasone | Clonidine | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Moderate | 1 | [
[
[
251,
24,
1020
]
],
[
[
251,
24,
1512
],
[
1512,
40,
1020
]
],
[
[
251,
6,
8374
],
[
8374,
45,
1020
]
],
[
[
251,
7,
5918
],
[
5918,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonidine"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Clonidine (Compound)
Betamethasone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clonidine (Compound)
Betamethasone (Compound) upregulates SLC22A5 (Gene) and SLC22A... |
DB01088 | DB05578 | 714 | 330 | [
"DDInter908",
"DDInter1566"
] | Iloprost | Ramucirumab | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Major | 2 | [
[
[
714,
25,
330
]
],
[
[
714,
24,
41
],
[
41,
63,
330
]
],
[
[
714,
24,
901
],
[
901,
24,
330
]
],
[
[
714,
63,
1100
],
[
1100,
24,... | [
[
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomiln... | Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran an... |
DB00543 | DB12141 | 87 | 971 | [
"DDInter82",
"DDInter817"
] | Amoxapine | Gilteritinib | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
87,
24,
971
]
],
[
[
87,
23,
112
],
[
112,
23,
971
]
],
[
[
87,
24,
485
],
[
485,
24,
971
]
],
[
[
87,
24,
823
],
[
823,
63,
... | [
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pen... |
DB00860 | DB11827 | 891 | 433 | [
"DDInter1513",
"DDInter669"
] | Prednisolone | Ertugliflozin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
891,
24,
433
]
],
[
[
891,
40,
1103
],
[
1103,
23,
433
]
],
[
[
891,
64,
646
],
[
646,
24,
433
]
],
[
[
891,
63,
1020
],
[
1020,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a ... | Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Prednisolone may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a moderate interaction that could exacerbate ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.